Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kissei Pharmaceutical Co., Ltd

https://www.kissei.co.jp/

Latest From Kissei Pharmaceutical Co., Ltd

Ipsen Hungry For More Deals After Swallowing Epizyme

Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.

M & A Cancer

Biotechs Stage No-Show As China’s STAR Market Marks Third Anniversary

To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.

China Financing

China's mRNA Shot Shows Benefits Over Older COVID Vaccines

Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.

China Clinical Trials

BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition

Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.

M & A Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Kissei Yakuhin Kogyo Co., Ltd.
UsernamePublicRestriction

Register